Pfizer, Novartis Get Advisory Panel Backing For General Methods Of Meningococcal Vaccine Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer appears to be slightly ahead of Novartis in planning a Phase III clinical trial of a vaccine against meningococcal serogroup B, with an anticipated start date later this year.